Brief: Ascentage Pharma Group International Says To Grant To Innovent Suzhou Right To Develop Hqp1351
14/07/2021 15:47
July 14 (Reuters) - Ascentage Pharma Group International
6855.HK :
* ASCENTAGE PHARMA GROUP INTERNATIONAL - ASCENTAGE AGREED TO
GRANT
TO INNOVENT SUZHOU RIGHT TO DEVELOP HQP1351 IN FIELD IN LICENSED
TERRITORY
Further company coverage: 6855.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up